Brief: Eiger BioPharmaceuticals Q2 product revenue USD 4.393 million
14/08/2023 23:34
Aug 14 (Reuters) - Eiger BioPharmaceuticals Q2 net income USD -20.695 million. * Q2 operating expenses USD 24.624 million * Q2 operating income USD -19.981 million * Q2 product revenue USD 4.393 million
Recent news on Eiger Biopharmaceuticals
See all newsBrief: Eiger Biopharmaceuticals On Sept 5, Bankruptcy Court Entered Order Confirming Fifth Amended Joint Plan Of Liquidation Of Co & Its Debtor Affiliates
Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar
Brief: Eiger Biopharmaceuticals And Amylyx Entered Into An Asset Purchase Agreement
Eiger BioPharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Eiger BioPharmaceuticals Inc expected to post a loss of $7.50 a share - Earnings Preview